EA201890012A1 - Способы и композиции для рнк-направляемого лечения инфекции, вызываемой вич - Google Patents
Способы и композиции для рнк-направляемого лечения инфекции, вызываемой вичInfo
- Publication number
- EA201890012A1 EA201890012A1 EA201890012A EA201890012A EA201890012A1 EA 201890012 A1 EA201890012 A1 EA 201890012A1 EA 201890012 A EA201890012 A EA 201890012A EA 201890012 A EA201890012 A EA 201890012A EA 201890012 A1 EA201890012 A1 EA 201890012A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- compositions
- hiv
- rna
- methods
- infection caused
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
- C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
- C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- AIDS & HIV (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Композиции для специфичного расщепления целевых последовательностей в ретровирусах, содержащие нуклеиновые кислоты, которые кодируют эндонуклеазу, ассоциированную с короткими палиндромными повторами, регулярно расположенными группами (CRISPR), и последовательность направляющей РНК, комплементарную одной или нескольким целевым последовательностям нуклеиновой кислоты в геноме ретровируса.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562169384P | 2015-06-01 | 2015-06-01 | |
US201562169633P | 2015-06-02 | 2015-06-02 | |
US201662308320P | 2016-03-15 | 2016-03-15 | |
PCT/US2016/035141 WO2016196539A2 (en) | 2015-06-01 | 2016-06-01 | Methods and compositions for rna-guided treatment of hiv infection |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201890012A1 true EA201890012A1 (ru) | 2018-05-31 |
EA037359B1 EA037359B1 (ru) | 2021-03-17 |
Family
ID=57442165
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201890012A EA037359B1 (ru) | 2015-06-01 | 2016-06-01 | Способы и композиции для рнк-направляемого лечения инфекции, вызываемой вич |
Country Status (16)
Country | Link |
---|---|
US (3) | US11298410B2 (ru) |
EP (2) | EP3919622A1 (ru) |
JP (1) | JP6968416B2 (ru) |
KR (2) | KR20230110368A (ru) |
CN (1) | CN108025188A (ru) |
AU (2) | AU2016270702B2 (ru) |
CA (1) | CA2987927C (ru) |
DK (1) | DK3302709T3 (ru) |
EA (1) | EA037359B1 (ru) |
ES (1) | ES2886480T3 (ru) |
HK (1) | HK1253882A1 (ru) |
MX (1) | MX2017015582A (ru) |
PL (1) | PL3302709T3 (ru) |
SG (1) | SG10201914137YA (ru) |
WO (1) | WO2016196539A2 (ru) |
ZA (1) | ZA201708236B (ru) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013066438A2 (en) | 2011-07-22 | 2013-05-10 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
EA037850B1 (ru) | 2013-08-29 | 2021-05-27 | Тэмпл Юниверсити Оф Зе Коммонвэлс Систем Оф Хайе Эдьюкейшн | Способы и композиции для рнк-направленного лечения вич-инфекции |
US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
US9228207B2 (en) | 2013-09-06 | 2016-01-05 | President And Fellows Of Harvard College | Switchable gRNAs comprising aptamers |
US20150165054A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting caspase-9 point mutations |
US10077453B2 (en) | 2014-07-30 | 2018-09-18 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
CN108025188A (zh) | 2015-06-01 | 2018-05-11 | 天普大学-联邦高等教育系统 | 用于hiv感染的rna导向治疗的方法和组合物 |
CN108779447A (zh) * | 2015-09-28 | 2018-11-09 | 天普大学-联邦高等教育系统 | 用于hiv感染的rna引导治疗的方法和组合物 |
EP3365357B1 (en) | 2015-10-23 | 2024-02-14 | President and Fellows of Harvard College | Evolved cas9 proteins for gene editing |
AU2017306676B2 (en) | 2016-08-03 | 2024-02-22 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
AU2017308889B2 (en) | 2016-08-09 | 2023-11-09 | President And Fellows Of Harvard College | Programmable Cas9-recombinase fusion proteins and uses thereof |
US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
SG11201903089RA (en) | 2016-10-14 | 2019-05-30 | Harvard College | Aav delivery of nucleobase editors |
WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
WO2018165504A1 (en) | 2017-03-09 | 2018-09-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
US11542496B2 (en) | 2017-03-10 | 2023-01-03 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
IL306092A (en) | 2017-03-23 | 2023-11-01 | Harvard College | Nucleic base editors that include nucleic acid programmable DNA binding proteins |
US20200140865A1 (en) * | 2017-04-17 | 2020-05-07 | Temple University - Of The Commonwealth System Of Higher Education | An hiv-1 eradication strategy employing nanoformulated anti-retroviral drugs and gene editing agents |
WO2018209320A1 (en) | 2017-05-12 | 2018-11-15 | President And Fellows Of Harvard College | Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation |
JP2020534795A (ja) | 2017-07-28 | 2020-12-03 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ファージによって支援される連続的進化(pace)を用いて塩基編集因子を進化させるための方法および組成物 |
WO2019139645A2 (en) | 2017-08-30 | 2019-07-18 | President And Fellows Of Harvard College | High efficiency base editors comprising gam |
US11788088B2 (en) * | 2017-09-26 | 2023-10-17 | The Board Of Trustees Of The University Of Illinois | CRISPR/Cas system and method for genome editing and modulating transcription |
US11795443B2 (en) | 2017-10-16 | 2023-10-24 | The Broad Institute, Inc. | Uses of adenosine base editors |
WO2020150499A1 (en) * | 2019-01-16 | 2020-07-23 | Fred Hutchinson Cancer Research Center | Methods to tag and isolate cells infected with the human immunodeficiency virus |
JP2022526908A (ja) | 2019-03-19 | 2022-05-27 | ザ ブロード インスティテュート,インコーポレーテッド | 編集ヌクレオチド配列を編集するための方法および組成物 |
EP4114952A4 (en) * | 2020-03-05 | 2024-05-08 | Univ Nebraska | CRISPR/CAS9 SYSTEM FOR THE TREATMENT OF MULTI-STRAIN HIV-1 |
AU2021267940A1 (en) | 2020-05-08 | 2022-12-08 | President And Fellows Of Harvard College | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
CN112322587A (zh) * | 2020-09-17 | 2021-02-05 | 杭州市第一人民医院 | 一种带Cas9基因的人源可诱导多能干细胞系、构建方法、鉴定方法及应用 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
JP6576904B2 (ja) * | 2013-04-04 | 2019-09-18 | トラスティーズ・オブ・ダートマス・カレッジ | HIV−1プロウイルスDNAのinvivo切除のための組成物及び方法 |
EA037850B1 (ru) * | 2013-08-29 | 2021-05-27 | Тэмпл Юниверсити Оф Зе Коммонвэлс Систем Оф Хайе Эдьюкейшн | Способы и композиции для рнк-направленного лечения вич-инфекции |
CN103923911B (zh) | 2014-04-14 | 2016-06-08 | 上海金卫生物技术有限公司 | CRISPR-Cas9特异性敲除人CCR5基因的方法以及用于特异性靶向CCR5基因的sgRNA |
CN104480144B (zh) * | 2014-12-12 | 2017-04-12 | 武汉大学 | 用于艾滋病基因治疗的CRISPR/Cas9重组慢病毒载体及其慢病毒 |
CN108025188A (zh) * | 2015-06-01 | 2018-05-11 | 天普大学-联邦高等教育系统 | 用于hiv感染的rna导向治疗的方法和组合物 |
CN108779447A (zh) | 2015-09-28 | 2018-11-09 | 天普大学-联邦高等教育系统 | 用于hiv感染的rna引导治疗的方法和组合物 |
CA3001130A1 (en) | 2015-10-16 | 2017-04-20 | Temple University - Of The Commonwealth System Of Higher Education | Methods and compositions utilizing cpf1 for rna-guided gene editing |
AU2016366229A1 (en) | 2015-12-09 | 2018-05-17 | Excision Biotherapeutics, Inc. | Gene editing methods and compositions for eliminating risk of JC virus activation and PML (progressive multifocal leukoencephalopathy) during immunosuppresive therapy |
US9925425B2 (en) | 2016-03-17 | 2018-03-27 | Acushnet Company | Golf ball incorporating at least three adjacent ionomeric and/or HNP-based layers having multiple related property gradients there between |
US20190093091A1 (en) | 2016-04-06 | 2019-03-28 | Temple University - Of The Commonwealth System Of Higher Education | Compositions for eradicating flavivirus infections in subjects |
US20190093092A1 (en) | 2016-05-05 | 2019-03-28 | Temple University - Of The Commonwealth System Of Higher Education | Rna guided eradication of varicella zoster virus |
US20190256844A1 (en) | 2016-06-07 | 2019-08-22 | Temple University - Of The Commonwealth System Of Higher Education | Rna guided compositions for preventing and treating hepatitis b virus infections |
US20190085326A1 (en) | 2016-09-14 | 2019-03-21 | Temple University - Of The Commonwealth System Of Higher Education | Negative feedback regulation of HIV-1 by gene editing strategy |
WO2018071623A2 (en) | 2016-10-12 | 2018-04-19 | Temple University - Of The Commonwealth System Of Higher Education | Combination therapies for eradicating flavivirus infections in subjects |
US10737984B2 (en) | 2016-11-30 | 2020-08-11 | Hrl Laboratories, Llc | Formulations and methods for 3D printing of ceramic matrix composites |
WO2018140269A1 (en) | 2017-01-26 | 2018-08-02 | Excision Biotherapeutics, Inc. | Lentivirus and non-integrating lentivirus as viral vector to deliver crispr therapeutic |
WO2018152418A1 (en) | 2017-02-17 | 2018-08-23 | Temple University - Of The Commonwealth System Of Higher Education | Gene editing therapy for hiv infection via dual targeting of hiv genome and ccr5 |
US20200140865A1 (en) | 2017-04-17 | 2020-05-07 | Temple University - Of The Commonwealth System Of Higher Education | An hiv-1 eradication strategy employing nanoformulated anti-retroviral drugs and gene editing agents |
-
2016
- 2016-06-01 CN CN201680045342.2A patent/CN108025188A/zh active Pending
- 2016-06-01 MX MX2017015582A patent/MX2017015582A/es unknown
- 2016-06-01 AU AU2016270702A patent/AU2016270702B2/en active Active
- 2016-06-01 WO PCT/US2016/035141 patent/WO2016196539A2/en active Application Filing
- 2016-06-01 PL PL16804274T patent/PL3302709T3/pl unknown
- 2016-06-01 US US15/578,372 patent/US11298410B2/en active Active
- 2016-06-01 EA EA201890012A patent/EA037359B1/ru unknown
- 2016-06-01 SG SG10201914137YA patent/SG10201914137YA/en unknown
- 2016-06-01 EP EP21172750.8A patent/EP3919622A1/en active Pending
- 2016-06-01 JP JP2017562290A patent/JP6968416B2/ja active Active
- 2016-06-01 KR KR1020237022586A patent/KR20230110368A/ko active Application Filing
- 2016-06-01 KR KR1020177037584A patent/KR102553518B1/ko active IP Right Grant
- 2016-06-01 EP EP16804274.5A patent/EP3302709B1/en active Active
- 2016-06-01 CA CA2987927A patent/CA2987927C/en active Active
- 2016-06-01 ES ES16804274T patent/ES2886480T3/es active Active
- 2016-06-01 DK DK16804274.5T patent/DK3302709T3/da active
-
2017
- 2017-12-04 ZA ZA2017/08236A patent/ZA201708236B/en unknown
-
2018
- 2018-10-11 HK HK18113022.5A patent/HK1253882A1/zh unknown
-
2020
- 2020-05-15 US US16/875,271 patent/US11273209B2/en active Active
- 2020-09-10 US US17/017,037 patent/US20210052709A1/en active Pending
-
2022
- 2022-03-17 AU AU2022201875A patent/AU2022201875A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EA037359B1 (ru) | 2021-03-17 |
US11273209B2 (en) | 2022-03-15 |
US20210052709A1 (en) | 2021-02-25 |
US20200282025A1 (en) | 2020-09-10 |
MX2017015582A (es) | 2018-09-06 |
ZA201708236B (en) | 2019-12-18 |
EP3302709A4 (en) | 2019-01-23 |
PL3302709T3 (pl) | 2021-12-06 |
WO2016196539A2 (en) | 2016-12-08 |
EP3302709B1 (en) | 2021-05-19 |
EP3302709A2 (en) | 2018-04-11 |
AU2016270702B2 (en) | 2022-01-20 |
US20180296649A1 (en) | 2018-10-18 |
AU2016270702A1 (en) | 2017-12-21 |
KR20230110368A (ko) | 2023-07-21 |
SG10201914137YA (en) | 2020-02-27 |
CA2987927A1 (en) | 2016-12-08 |
AU2022201875A1 (en) | 2022-04-07 |
KR20180023911A (ko) | 2018-03-07 |
HK1253882A1 (zh) | 2019-07-05 |
ES2886480T3 (es) | 2021-12-20 |
JP6968416B2 (ja) | 2021-11-17 |
US11298410B2 (en) | 2022-04-12 |
EP3919622A1 (en) | 2021-12-08 |
DK3302709T3 (da) | 2021-08-23 |
KR102553518B1 (ko) | 2023-07-07 |
JP2018516572A (ja) | 2018-06-28 |
WO2016196539A3 (en) | 2017-02-16 |
CA2987927C (en) | 2024-03-19 |
CN108025188A (zh) | 2018-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201890012A1 (ru) | Способы и композиции для рнк-направляемого лечения инфекции, вызываемой вич | |
WO2017058658A3 (en) | Methods and compositions for rna-guided treatment of hiv infection | |
EA201600226A1 (ru) | Способы и композиции для рнк-направленного лечения вич-инфекции | |
MX2022006603A (es) | Vacuna contra el virus de la influenza de amplio espectro. | |
AR103927A1 (es) | Método para mejorar la habilidad de resistir a adn de virus que infectan plantas | |
EA201890999A1 (ru) | Вакцина против вируса простого герпеса | |
NZ728437A (en) | Methods for increasing cas9-mediated engineering efficiency | |
WO2017213898A3 (en) | Rna guided compositions for preventing and treating hepatitis b virus infections | |
MX2018010633A (es) | Acido desoxirribonucleico (adn) lineal duplex de extremos cerrados para transferencia genica no viral. | |
RU2022103603A (ru) | Направляемые нуклеиновыми кислотами нуклеазы | |
MX2017005672A (es) | Erradicacion guiada de arn de virus jc mano y otros poliomavirus. | |
WO2016183402A3 (en) | Methods of making and using guide rna for use with cas9 systems | |
BR112018010681A2 (pt) | método para modificar um sítio alvejado, complexo de enzima de modificação de ácido nucleico, e, ácido nucleico. | |
SG10201805815YA (en) | Rna-guided gene drives | |
NZ712727A (en) | Compositions and methods of nucleic acid-targeting nucleic acids | |
WO2016183438A8 (en) | Self-targeting genome editing system | |
TW201613612A (en) | Substituted nucleosides, nucleotides and analogs thereof | |
PH12016502555A1 (en) | Methods of preparing substituted nucleotide analogs | |
WO2015112896A3 (en) | Methods and compositions for sequences guiding cas9 targeting | |
MD4760B1 (ru) | Композиции и методы лечения инфекций, вызванных вирусами гепатита В и гепатита D | |
EA201792538A1 (ru) | Способ биологического получения метакриловой кислоты | |
MX2018005872A (es) | Profarmacos de acido nucleico. | |
WO2015168600A3 (en) | Methods and apparatus for transformation of naturally competent cells | |
MX2018003290A (es) | Medios para el tratamiento del vih. | |
CL2016002737A1 (es) | Nucleasa efectora tal para la inactivación específica del correceptor del vih ccr5 |